Brand new #factsheet from HARMLESS, on #ToxFAIRy, the HARMLESS software solution for automated toxicity scoring and FAIRification of data!
ToxFAIRy is developed as a tool supporting the Safe Innovation Approach (#SIA) by automating and enhancing the efficiency of toxicity assessment and material prioritization, while following #FAIR principles. It is a new data analysis and management solution that automates high throughput in vitro screening data to increase the efficiency of clustering, ranking, prioritizing, and reading across nanomaterials and advanced materials. ToxFAIRY uses a novel approach for in vitro high-throughput screening (HTS)-based toxicity assessment, which is used for efficient clustering, ranking, prioritization, and read across of nanomaterials and advanced materials.
Have a look to the factsheet here: https://lnkd.in/ds6w9V6k
This work has been coordinated by the partners IDEAconsult, Misvik Biology. The factsheet has been created by HARMLESS C&D manager, BNN - BioNanoNet.
A Relentless Explorer on the Frontier of Protein Design, Lab Automation and Therapeutics! Let's challenge the status quo together!
3moFantastic accomplishment and outstanding work! 👏 I’m curious – does the Cradle algorithm also consider other therapeutic properties of the designed antibody, like immunogenicity or overall 'human-likeness'? The 8x increase in affinity is truly impressive, but I’d love to hear how the new design compares in terms of other therapeutic-relevant features.